**Bromisoval**

**Cat. No.:** HY-B2113  
**CAS No.:** 496-67-3  
**Molecular Formula:** C₆H₁₁BrN₂O₂  
**Molecular Weight:** 223.07  
**Target:** Others  
**Pathway:** Others  
**Storage:**  
- Powder: -20°C, 3 years; 4°C, 2 years  
- In solvent: -80°C, 6 months; -20°C, 1 month

**SOLVENT & SOLUBILITY**

**In Vitro**  
DMSO: 300 mg/mL (1344.87 mM; Need ultrasonic and warming)

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Mass 1 mg</th>
<th>Mass 5 mg</th>
<th>Mass 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>4.4829 mL</td>
<td>22.145 mL</td>
<td>44.8290 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.8966 mL</td>
<td>4.4829 mL</td>
<td>8.9658 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.4483 mL</td>
<td>2.2414 mL</td>
<td>4.4829 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

**BIOLOGICAL ACTIVITY**

**Description**  
Bromisoval has anti-inflammatory effects.

**In Vitro**  
Bromisoval (BU) suppresses nitric oxide (NO) releasing and proinflammatory cytokine expression in lipopolysaccharide (LPS)-treat BV2 cells, a murine microglial cell line. Bromisoval suppresses LPS-inducing phosphorylation of signal transducer and activator of transcription 1 (STAT1) and expression of interferon regulatory factor 1 (IRF1). The Janus kinase 1 (JAK1) inhibitor filgotinib suppresses the NO release much more weakly than that of Bromisoval, although filgotinib almost completely prevents LPS-inducing STAT1 phosphorylation. Knockdown of JAK1, STAT1, or IRF1 does not affect the suppressive effects of Bromisoval on LPS-inducing NO. A combination of Bromisoval and filgotinib synergistically suppress the NO releasing. The mitochondrial complex I inhibitor rotenone, which does not prevent STAT1 phosphorylation or IRF1 expression, suppresses proinflammatory mediator expression less significantly than Bromisoval. Bromisoval and rotenone reduce intracellular ATP (iATP) levels to a similar extent. A combination of rotenone and filgotinib suppress NO release in LPS-treated BV2 cells as strongly as Bromisoval[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**  
Bromisoval (Bromvaletone) and carboxmal are the most potent central depressants within each series. Depressant activities
(ISD<sub>50</sub> values) and acute toxicities (LD<sub>50</sub> values) in male mice after intraperitoneal injection of Bromisoval are 0.35 (0.30-0.39) and 3.25 (2.89-3.62) mmol/kg, respectively<sup>2</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Kinase Assay<sup>[1]</sup>
Conditioning media are obtained from BV2 cell cultures that have been incubated for 24 h in E2 medium containing 1 μg/ml LPS, with or without Bromisoval (BU) (1-100 μg/mL) or other agents, and subjected to NO determination. To normalize the releasing NO level by the cellular protein contents, cells are solubilized with RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM sodium chloride, 0.5% w/v sodium deoxycholate, 0.1% w/v sodium dodecyl sulfate, 1.0% w/v NP-40 substitute) and the protein contents are determined by BCA protein assay reagents<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Cell Assay<sup>[1]</sup>
Murine microglial cell line BV2 is used. BV2 cells are maintained in medium supplemented with 10% fetal bovine serum. BV2 cells are seeded onto wells in 4-well culture plates and incubated with LPS for 30 min to 24 h. When the effects of Bromisoval (BU) or other agents are investigated, BV2 cells are incubated with the appropriate agent (e.g. Bromisoval) for 30 min before the addition of LPS<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Animal Administration<sup>[2]</sup>
Suspensions of the compounds (including Bromisoval) in aqueous 0.5% carboxymethyl cellulose are administered intraperitoneally to adult male albino mice weighing 25-35 g. All tests are performed on groups of ten mice<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES


**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898                     Fax: 609-228-5909                     E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA